News

Shares of Becton, Dickinson (NYSE: BDX) were up by more than 6% as of 12:15 p.m. ET Monday, after having climbed by as much as 8.5% shortly after 10 a.m. The medical equipment company announced

Fool.com contributor Parkev Tatevosian evaluates AT&T's (NYSE: T) prospects to determine whether its dividend payments are sustainable in the long run.

*Stock prices used were the afternoon prices

When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products. These could make interesting investment opportunities. But they often

For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an

Think small. It's one of the best ideas for investors seeking to reap returns that trounce the overall market.

Three Motley Fool contributors identified small-cap stocks that they think could

Even if you don't recognize the name Viatris (NASDAQ: VTRS), you may have come in very close contact with this pharma company. It sells a wide variety of generic drugs -- such as generic Zyrtec

In retirement, seniors on average see an annual shortfall of about $4,000 between the income they generate and the expenses they incur, according to data from the Bureau of Labor Statistics

Investors looking for stocks with explosive growth potential would do well to take a gander at the biotech industry. Clinical and regulatory wins can fuel excellent stock market performances for

Last April, AT&T (NYSE: T) spun off WarnerMedia and merged it with Discovery to create new-media giant Warner Bros. Discovery (NASDAQ: WBD). That spinoff, along with its divestment of DirecTV in

CRISPR Therapeutics (NASDAQ: CRSP) may be a few months away from a transformation. The company itself isn't changing, but its financial picture may be about to do so. That's because by year-end

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q2 2023 Earnings CallJul 20, 2023, 9:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Vir Biotechnology (NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. The stock is

Over the past three years, Novavax (NASDAQ: NVAX) has lost an astonishing 92% of its value on the market. The reason for that is no secret. The biotech quickly established itself in the race to

There's no healthcare company that's worth anywhere near $1 trillion today. But within the next 10 years, that's likely to change, given the many growth opportunities emerging in the industry. Two

A high-yielding dividend stock can generate lots of dividend income for your portfolio. But that doesn't mean you should buy a stock only because of its yield. Dividends are never guaranteed and

Shares of Novavax (NASDAQ: NVAX) have been jumping in the past month, and they are up around 25% since April. There's an influx of money coming its way due to unused COVID shots in Canada, which

After a down 2022, growth stocks are making a big comeback this year. The S&P 500 Growth index is up more than 21% this year, while the S&P 500 Value index is up just a little more than 13%

You need money to make money with stocks. While there's no minimum you have to invest, $5,000 is a good figure I strive for as a minimum. It means you've got some decent skin in the game where

Is it over yet?

After 10 rough days of almost unabated selling, shares of telecom giant AT&T (NYSE: T) finally bounced back on Wednesday, posting a gain of 7.8% through 12:25 p.m. ET and erasing

Pfizer (NYSE: PFE) and Viatris (NASDAQ: VTRS) have a common past. That's because Viatris came about a few years ago when Pfizer's Upjohn business merged with generic drug giant, Mylan. Since, their